FDA Breakthrough for Altimmune: Pemvidutide Shows Statistically Significant Improvements in MASH Patients
Market Chameleon (Mon, 5-Jan 10:32 AM)
ALT’s Pemvidutide Shows Significant Antifibrotic Benefits at 48 Weeks: Phase 2b Results Point Toward Phase 3 Trial
Market Chameleon (Mon, 22-Dec 10:19 AM)
ALT’s Pemvidutide Achieves Strong 48-Week Efficacy in MASH: Significant Reductions in Liver Fibrosis and Sustained Weight Loss Highlight Phase 2b Results
Market Chameleon (Fri, 19-Dec 7:06 AM)
ALT Announces CEO Transition as Pemvidutide Approaches Phase 3 Milestone
Market Chameleon (Mon, 1-Dec 8:12 AM)
